Actinium Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Actinium Pharmaceuticals

ATNM 1.430

+0.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

PreviousNext

From: Old Stock Collector	6/26/2023 1:22:01 AM
	of 1

NEW YORK, June 23, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six abstracts accepted for oral and poster presentation at the upcoming Society for Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting, which will be held in Chicago, June 24-27, 2023. These abstracts exhibit the breadth of Actinium's technological and clinical endeavors over the past year that are now culminating in targeted radiotherapies that meaningfully improve the outcomes of cancer patients. https://finance.yahoo.com/news/actinium-pharma-highlights-six-abstracts-120000736.html

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

PreviousNext